The XEN® 45 Gel Stent is a hydrophilic, non-inflammatory, subconjunctival gelatin stent. FDA cleared in November 2016 for the management of refractory glaucoma, XEN® provides an ab interno approach, reducing the risk of bleb infection or leak, while bypassing the natural drainage pathways that often become obstructed and cause elevated IOP. The gelatin stent swells when hydrated, helping to maintain its intended position. Adapting to the shape of the surrounding tissues, a permanent channel is formed, connecting the anterior chamber to the subconjunctival space.
Following pretreatment of the target area with Mitosol (mitomycin for solution) 0.2 mg/mL, the beveled needle tip of the injector is advanced through a peripheral corneal incision (1–2 mm anterior to the limbus) and across the anterior chamber toward the target quadrant, using an ab interno approach. The needle tip is then aligned with the desired entry point of the trabecular meshwork and advanced through the trabecular meshwork (under gonioscopic guidance) and sclera. The bevel is visualized as it enters the subconjunctival space. The gelatin stent is then released in the subconjunctival space and the injector removed from the eye. When properly positioned, approximately 2 mm and 1 mm of the stent length are visible in the subconjunctival space and anterior chamber, respectively. After implantation, the conjunctiva is closed and the viscoelastic is irrigated and aspirated as needed. Seidel testing is then performed to ensure that there is no leakage of aqueous humor from the anterior chamber or conjunctiva.¹
Learn more about the XEN 45 Gel Stent
¹ Grover DS, Flynn WJ, Bashford KP, Lewis RA, Duh Y-J, Nangia RS, Niksch B, Performance and Safety of a New Ab Interno Gelatin Stent in Refractory Glaucoma at 12 Months, American Journal of Ophthalmology (2017), doi: 10.1016/j.ajo.2017.07.023
© 2018 Allergan. All rights reserved. XEN® is a registered trademark of AqueSys, Inc., an Allergan affiliate. Allergan® and its design are trademarks of Allergan, Inc.
WMI-055 Rev 11/2019